EN
首页 资讯 期刊 导师 问答 求职 发Paper 文献直达 高级搜索 期刊列表
当前位置： X-MOL 学术 › J. Hematol. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Correction to: MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies
Journal of Hematology & Oncology ( IF 28.5 ) Pub Date : 2021-09-03 , DOI: 10.1186/s13045-021-01152-9
Seyed Esmaeil Ahmadi 1 , Samira Rahimi 1 , Bahman Zarandi 1 , Rouzbeh Chegeni 2 , Majid Safa 1, 3
Affiliation  

The original article [1] incorrectly states that OMO-1 is a MYC inhibitor in two instances: in the Direct MYC Inhibition sub-section of the MYC Inhibitors section, and in Table 3.

The authors wish to clarify that OMO-1 is not a MYC inhibitor, and its mentions in the original article should be disregarded.

  1. 1.

    Ahmadi SE, et al. MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. J Hematol Oncol. 2021;14:121. https://doi.org/10.1186/s13045-021-01111-4.

    Article PubMed PubMed Central Google Scholar

Download references

Affiliations

  1. Department of Hematology and Blood Banking, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran

    Seyed Esmaeil Ahmadi, Samira Rahimi, Bahman Zarandi & Majid Safa

  2. Medical Laboratory Sciences Program, College of Health and Human Sciences, Northern Illinois University, DeKalb, IL, USA

    Rouzbeh Chegeni

  3. Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran

    Majid Safa

Authors
  1. Seyed Esmaeil AhmadiView author publications

    You can also search for this author in PubMed Google Scholar

  2. Samira RahimiView author publications

    You can also search for this author in PubMed Google Scholar

  3. Bahman ZarandiView author publications

    You can also search for this author in PubMed Google Scholar

  4. Rouzbeh ChegeniView author publications

    You can also search for this author in PubMed Google Scholar

  5. Majid SafaView author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Rouzbeh Chegeni or Majid Safa.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

Verify currency and authenticity via CrossMark

Cite this article

Ahmadi, S.E., Rahimi, S., Zarandi, B. et al. Correction to: MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. J Hematol Oncol 14, 135 (2021). https://doi.org/10.1186/s13045-021-01152-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13045-021-01152-9

中文翻译：
更正：MYC：一种多用途致癌基因，对血液恶性肿瘤具有预后和治疗意义

原始文章 [1] 在两种情况下错误地指出 OMO-1 是 MYC 抑制剂：在 MYC 抑制剂部分的直接 MYC 抑制子部分和表 3 中。

作者希望澄清 OMO-1 不是 MYC 抑制剂，应忽略原始文章中的提及。

  1. 1.

    艾哈迈迪 SE，等。MYC：一种多用途致癌基因，对血液恶性肿瘤具有预后和治疗意义。J Hematol Oncol。2021；14:121。https://doi.org/10.1186/s13045-021-01111-4。

    文章 PubMed PubMed Central Google Scholar

下载参考

隶属关系

  1. 伊朗医科大学联合医学院血液学和血库系，伊朗德黑兰

    赛义德·埃斯梅尔·艾哈迈迪、萨米拉·拉希米、巴赫曼·扎兰迪和马吉德·萨法

  2. 美国伊利诺伊州迪卡尔布北伊利诺伊大学健康与人类科学学院医学实验室科学计划

    鲁兹贝·谢格尼

  3. 细胞和分子研究中心，伊朗医科大学，伊朗德黑兰

    马吉德·萨法

作者
  1. Seyed Esmaeil Ahmadi查看作者出版物

    您也可以在PubMed Google Scholar中搜索此作者 

  2. Samira Rahimi查看作者出版物

    您也可以在PubMed Google Scholar中搜索此作者 

  3. Bahman Zarandi查看作者出版物

    您也可以在PubMed Google Scholar中搜索此作者 

  4. Rouzbeh Chegeni查看作者出版物

    您也可以在PubMed Google Scholar中搜索此作者 

  5. Majid Safa查看作者出版物

    您也可以在PubMed Google Scholar中搜索此作者 

通讯作者

与 Rouzbeh Chegeni 或 Majid Safa 的通信。

出版商说明

Springer Nature 对已出版地图和机构附属机构中的管辖权主张保持中立。

开放获取本文根据知识共享署名 4.0 国际许可协议获得许可，允许以任何媒体或格式使用、共享、改编、分发和复制，只要您适当注明原作者和来源，提供链接到知识共享许可，并指出是否进行了更改。本文中的图像或其他第三方材料包含在文章的知识共享许可中，除非在材料的信用额度中另有说明。如果文章的知识共享许可中未包含材料，并且您的预期用途未得到法律法规的允许或超出允许的用途，则您需要直接从版权所有者处获得许可。要查看此许可证的副本，请访问 http://creativecommons.org/licenses/by/4.0/。

重印和许可

通过 CrossMark 验证货币和真实性

引用这篇文章

Ahmadi, SE, Rahimi, S., Zarandi, B.等。更正：MYC：一种多用途致癌基因，对血液恶性肿瘤具有预后和治疗意义。J Hematol Oncol 14, 135 (2021)。https://doi.org/10.1186/s13045-021-01152-9

下载引文

  • 发表：

  • DOI : https://doi.org/10.1186/s13045-021-01152-9
更新日期：2021-09-03
  点击分享   查看原文
点击收藏
公开下载
阅读更多本刊最新论文 本刊介绍/投稿指南
down
wechat
bug